- Home
- PBFS vs AVTX Comparison
PBFS vs AVTX Comparison
Compare PBFS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBFS | AVTX |
|---|---|---|
| Founded | 1889 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.8M | 339.9M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PBFS | AVTX |
|---|---|---|
| Price | $14.01 | $17.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $32.57 |
| AVG Volume (30 Days) | 6.6K | ★ 488.8K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.66 |
| EPS | ★ 0.67 | N/A |
| Revenue | $14,953,000.00 | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.52 | ★ N/A |
| Revenue Growth | 15.23 | ★ 2312.27 |
| 52 Week Low | $10.60 | $3.39 |
| 52 Week High | $15.18 | $20.72 |
Technical Indicators
Market Signals| Indicator | PBFS | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 54.92 |
| Support Level | $12.89 | $17.18 |
| Resistance Level | $14.08 | $19.80 |
| Average True Range (ATR) | 0.28 | 1.55 |
| MACD | -0.06 | 0.29 |
| Stochastic Oscillator | 8.25 | 66.50 |
Price Performance
Historical ComparisonAbout PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).